| Sarcoma treatment in the era of molecular medicine TGP Grünewald, M Alonso, S Avnet, A Banito, S Burdach, F Cidre‐Aranaz, ... EMBO molecular medicine 12 (11), e11131, 2020 | 309 | 2020 |
| Circulating tumor cells: a review of non–EpCAM-based approaches for cell enrichment and isolation MT Gabriel, LR Calleja, A Chalopin, B Ory, D Heymann Clinical chemistry 62 (4), 571-581, 2016 | 291 | 2016 |
| Tumour heterogeneity: the key advantages of single-cell analysis M Tellez-Gabriel, B Ory, F Lamoureux, MF Heymann, D Heymann International journal of molecular sciences 17 (12), 2142, 2016 | 234 | 2016 |
| Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice B Ory, MF Heymann, A Kamijo, F Gouin, D Heymann, F Redini Cancer: Interdisciplinary International Journal of the American Cancer …, 2005 | 202 | 2005 |
| Bisphosphonates: new therapeutic agents for the treatment of bone tumors D Heymann, B Ory, F Gouin, JR Green, F Rédini Trends in molecular medicine 10 (7), 337-343, 2004 | 174 | 2004 |
| Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma D Heymann, B Ory, F Blanchard, MF Heymann, P Coipeau, C Charrier, ... Bone 37 (1), 74-86, 2005 | 167 | 2005 |
| Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle F Lamoureux, M Baud’huin, L Rodriguez Calleja, C Jacques, M Berreur, ... Nature communications 5 (1), 3511, 2014 | 166 | 2014 |
| Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteries M Steenman, O Espitia, B Maurel, B Guyomarch, MF Heymann, ... Scientific Reports 8 (1), 3940, 2018 | 150 | 2018 |
| Mechanisms of resistance to conventional therapies for osteosarcoma L Marchandet, M Lallier, C Charrier, M Baud’huin, B Ory, F Lamoureux Cancers 13 (4), 683, 2021 | 128 | 2021 |
| Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma MR Ramsey, L He, N Forster, B Ory, LW Ellisen Cancer research 71 (13), 4373-4379, 2011 | 128 | 2011 |
| FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma MR Ramsey, C Wilson, B Ory, SM Rothenberg, W Faquin, AA Mills, ... The Journal of clinical investigation 123 (8), 3525-3538, 2013 | 120 | 2013 |
| Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process G Moriceau, B Ory, L Mitrofan, C Riganti, F Blanchard, R Brion, C Charrier, ... Cancer Research 70 (24), 10329-10339, 2010 | 119 | 2010 |
| Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation … B Ory, F Blanchard, S Battaglia, F Gouin, F Redini, D Heymann Molecular pharmacology 71 (1), 333-343, 2007 | 110 | 2007 |
| MicroRNA‐17‐5p reduces inflammation and bone erosions in mice with collagen‐induced arthritis and directly targets the JAK/STAT pathway in rheumatoid arthritis fibroblast‐like … A Najm, FM Masson, P Preuss, S Georges, B Ory, T Quillard, S Sood, ... Arthritis & Rheumatology 72 (12), 2030-2039, 2020 | 98 | 2020 |
| A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma B Ory, MR Ramsey, C Wilson, DD Vadysirisack, N Forster, JW Rocco, ... The Journal of clinical investigation 121 (2), 809-820, 2011 | 95 | 2011 |
| Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme M Cheray, A Etcheverry, C Jacques, R Pacaud, G Bougras-Cartron, ... Molecular cancer 19 (1), 36, 2020 | 94 | 2020 |
| Origin and therapies of osteosarcoma B Moukengue, M Lallier, L Marchandet, M Baud’huin, F Verrecchia, B Ory, ... Cancers 14 (14), 3503, 2022 | 90 | 2022 |
| BYL719, a new α‐specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma B Gobin, MB Huin, F Lamoureux, B Ory, C Charrier, R Lanel, S Battaglia, ... International journal of cancer 136 (4), 784-796, 2015 | 87 | 2015 |
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate B Gobin, S Battaglia, R Lanel, J Chesneau, J Amiaud, F Rédini, B Ory, ... Cancer letters 344 (2), 291-298, 2014 | 80 | 2014 |
| Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival F Gouin, B Ory, F Rédini, D Heymann International journal of cancer 119 (5), 980-984, 2006 | 72 | 2006 |
